Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin +/- Anlotinib in Metastatic Breast Cancer
NCT05206656Phase 2Completed
- Sponsor
- Hunan Cancer Hospital
- Start
- Oct 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anlotinib in breast cancer (2 arms), sponsored by Hunan Cancer Hospital. Primary endpoint: Progression-Free Survival up to 6 months. Started Oct 2020; status: completed.
02
Drugs
anlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05206656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05206656.